RxDoctor Payments Data

Eduardo Cutie, MD

Neurology · Lauderdale Lakes, FLNPI 1932159670

Payments from drug & device makers

$11,979in general payments, 2019–2025

Across 675 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$1K
  • UCB, Inc.$1K
  • Amgen$706
  • Lilly USA, LLC$598
  • Teva Pharmaceuticals USA, Inc.$592
  • plus $5K from 42 others

What the payments were for

  • Speaking & faculty fees$2072%
  • Food & beverage$11,77298%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,979 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$35,493
Medicare patients
85
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5033$370,691
BotoxOnabotulinumtoxina161$200,912
GammakedImmune Globul G/Gly/Iga Avg 4617$170,316
NuplazidPimavanserin Tartrate13$60,773
NeuproRotigotine54$56,895
GocovriAmantadine Hcl13$43,758
AptiomEslicarbazepine Acetate11$26,565
Entacapone127$16,943
NamzaricMemantine Hcl/Donepezil Hcl13$16,931
Diclofenac Sodium482$13,579
UbrelvyUbrogepant12$12,712
Carbidopa-LevodopaCarbidopa/Levodopa751$11,787
QuliptaAtogepant11$11,345
Rivastigmine81$10,480
Memantine Hcl547$9,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$226$370,69133 claims
AbbVieBotox, Namzaric, Ubrelvy, Qulipta$2,399$241,899197 claims
Acadia Pharmaceuticals IncNuplazid$27$60,77313 claims
UCB, Inc.Neupro$1,026$56,89554 claims
MDD US Operations, LLCGocovri$136$43,75813 claims
Sunovion Pharmaceuticals Inc.Aptiom$430$26,56511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Lauderdale Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →